Credit: Maryna_Auramchuk / Shutterstock. Daiichi Sankyo has announced the first subject dosing in the Phase III DESTINYEndometrial01 trial of Enhertu (trastuzumab deruxtecan) plus rilvegostomig or ...

The first patient has been dosed in the DESTINY-Endometrial01 phase 3 trial evaluating ENHERTU ® (trastuzumab deruxtecan) in combination with rilvegostomig or pembrolizumab versus platinum-based ...

The first patient has been dosed in the DESTINY-Endometrial01 phase 3 trial evaluating ENHERTU ® (trastuzumab deruxtecan) in combination with rilvegostomig or pembrolizumab versus platinum-based ...

Even though it is a handheld console and therefore runs on weaker hardware compared to its contemporaries, a gap that felt even wider when it launched in 2004, the Nintendo DS ranked among the ...

Positive results from the DESTINY-Breast09 phase III trial showed Enhertu (trastuzumab deruxtecan) plus pertuzumab demonstrated a highly statistically significant and clinically meaningful improvement ...

The French Stellantis subsidiary DS unveiled the new DS N°4 in mid-May and has now also announced the prices for the French market. The battery-electric offshoot DS N°4 E-Tense starts in the Pallas ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.

It has been updated to include the missing portion. NEW YORK – A dual HER2-targeted combination of the antibody-drug conjugate Enhertu (trastuzumab deruxtecan) and the monoclonal antibody Perjeta ...

Presented at ASCO 2025, new data from the DESTINY-Breast09 trial showed that Enhertu plus pertuzumab cut the risk of disease progression or death by 44% compared to taxane, trastuzumab, and pertuzumab ...

In a prespecified interim analysis, ENHERTU plus pertuzumab reduced the risk of disease progression or death by 44% versus THP (based on a hazard ratio [HR] of 0.56; 95% confidence interval [CI] ...